Vertex director granted 2,866 stock options

Vertex Pharmaceuticals director Lloyd Carney received a fully vested stock option grant covering 2,866 shares of common stock.

Rhea-AI Filing Summary

Vertex Pharmaceuticals director Lloyd Carney received a fully vested stock option grant covering 2,866 shares of common stock. The option has an exercise price of $424.45 per share and expires on April 30, 2036. Following this award, Carney holds 2,866 stock options directly.

Insider Trade Summary

Grant/Award: 2,866 shares

Grant/Award 1 txn

Insider CARNEY LLOYD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,866	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,866 contracts (Direct)

Footnotes (1)

1. F1. Fully vested.

Key Figures

Option grant size: 2,866 options Exercise price: $424.45 per share Expiration date: April 30, 2036 +1 more

4 metrics

Option grant size 2,866 options Stock Option (Right to Buy) granted May 1, 2026

Exercise price $424.45 per share Strike price of stock option grant

Expiration date April 30, 2036 Option term end date

Options held after grant 2,866 options Total derivative holdings following transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Fully vested

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Fully vested financial

"footnote: Fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vertex (VRTX) director Lloyd Carney report in this Form 4 filing?

Lloyd Carney reported receiving a stock option grant for 2,866 shares. The options relate to Vertex common stock and were awarded as compensation, not through open-market buying or selling, and are held directly by Carney according to the filing.

How many Vertex (VRTX) stock options did Lloyd Carney receive?

Lloyd Carney received 2,866 stock options linked to Vertex common stock. The filing shows these options as the total derivative position following the transaction, indicating this grant established his reported option holdings in the company.

What is the exercise price and term of Lloyd Carney’s Vertex (VRTX) options?

The stock options have an exercise price of $424.45 per share and an expiration date of April 30, 2036. This gives Carney the right to buy Vertex common shares at that price until the stated expiration.

Are Lloyd Carney’s newly granted Vertex (VRTX) options vested?

The options are described as fully vested in the footnote. This means Carney can exercise the 2,866 options at the $424.45 strike price at any time before the April 30, 2036 expiration, subject to any applicable company or regulatory trading restrictions.

Is this Form 4 transaction a market purchase or sale of Vertex (VRTX) shares?

No, this Form 4 reflects a grant of stock options, not market trading. The transaction code “A” denotes a grant, award, or other acquisition of derivative securities as compensation, with no open-market buying or selling reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARNEY LLOYD

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$424.45	05/01/2026		A		2,866		(1)	04/30/2036	Common Stock	2,866	$0	2,866	D

Explanation of Responses:

1. Fully vested.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)